ABSTRACT
Introduction A major hurdle to HIV-1 eradication is the establishment of a latent viral reservoir early after primary infection. Several factors are known to influence the HIV-1 reservoir size and decay rate on suppressive antiretroviral treatment (ART), but little is known about the role of human genetic variation.
Methods We measured the reservoir size at three time points over a median of 5.4 years, and searched for associations between human genetic variation and two phenotypic readouts: the reservoir size at the first time point and its decay rate over the study period. We assessed the contribution of common genetic variants using genome-wide genotyping data from 797 patients with European ancestry enrolled in the Swiss HIV Cohort Study and searched for a potential impact of rare variants and exonic copy number variants using exome sequencing data generated in a subset of 194 study participants.
Results Genome- and exome-wide analyses did not reveal any significant association with the size of the HIV-1 reservoir or its decay rate on suppressive ART.
Conclusions Our results point to a limited influence of human genetics on the size of the HIV-1 reservoir and its long-term dynamics in successfully treated individuals.
Competing Interest Statement
H.F.G. has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, ViiV, Merck, Sandoz and Mepha. TK has received consulting/advisory board membership fees from Gilead Sciences and from ViiV Healthcare for work that has no connection to the work presented here. K.J.M. has received travel grants and honoraria from Gilead Sciences, Roche Diagnostics, GlaxoSmithKline, Merck Sharp & Dohme, Bristol-Myers Squibb, ViiV and Abbott; and the University of Zurich received research grants from Gilead Science, Roche, and Merck Sharp & Dohme for studies that Dr. Metzner serves as principal investigator, and advisory board honoraria from Gilead Sciences. A.R. reports support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, Pfizer and Abbvie, and an investigator initiated trial (IIT) grant from Gilead Sciences. All remuneration went to his home institution and not to A.R. personally, and all remuneration was provided outside the submitted work. All other authors declare no competing financial interests.
Funding Statement
This work was funded within the framework of the Swiss HIV Cohort Study (SNF grant# 33CS30_177499 to H.F.G.). The data were gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/180-health-care-providers). The work was furthermore supported by the Systems.X grant # 51MRP0_158328 (to N.B., J.B., J.F.,V.R., R.D.K., M.W., H.F.G. and K.J.M.), by SNF grant 324730B_179571 (to H.F.G.), SNF grant SNF 310030_141067/1 (to H.F.G. and K.J.M.), SNF grants no. PZ00P3-142411 and BSSGI0_155851 to R.D.K., the Yvonne-Jacob Foundation (to H.F.G.), the University of Zurich’s Clinical Research Priority Program viral infectious disease, ZPHI (to H.F.G) and the Vontobel Foundation (to H.F.G. and K.J.M.). M.W. is partially supported by the NCCR MARVEL, funded by the Swiss National Science Foundation.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to privacy reasons, the sensitivities associated with HIV infections, and the representativeness of the dataset, but is available on request.
